瑞典类风湿关节炎患者使用生物制剂与胃肠道穿孔风险:全国队列研究
托珠单抗组风险显著高于TNFi(校正HR 2.2),但所有生物制剂绝对风险均较低。
要点
- 托珠单抗较TNFi增加下消化道穿孔风险,校正HR 2.2(1.3-3.8)。
- 每451患者年托珠单抗替代TNFi治疗可额外发生1例消化道穿孔。
- 所有常用生物制剂的绝对穿孔风险均较低。
核心结论
- 托珠单抗与下消化道穿孔风险升高相关,但所有常用生物制剂的绝对风险仍较低,指南制定时应考虑该风险。
主要发现
- 下消化道穿孔的年龄和性别标化发生率:普通人群对照1.1(95%CI 1.0-1.3)/1000人年,未使用生物制剂患者1.6(1.5-1.7),TNFi治疗者1.8(1.4-3.6),托珠单抗治疗者4.5(2.7-10.4)。
- 校正糖皮质激素使用后,未使用生物制剂、TNFi、阿巴西普或利妥昔单抗治疗的RA患者风险与普通人群无差异,而托珠单抗组仍显著升高。
- 托珠单抗对比TNFi的下消化道穿孔校正HR为2.2(1.3-3.8),相当于每451患者年托珠单抗替代TNFi治疗可额外发生1例消化道穿孔。
临床怎么用
- 对RA患者选择生物制剂时,尤其存在消化道穿孔风险因素者,应考虑托珠单抗相对于TNFi的较高下消化道穿孔风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare incidence rates of gastrointestinal (GI) perforations between patients with RA and the general population, and between patients treated with tumour necrosis factor inhibitors (TNFi) and non-TNFi biologics. METHODS: In this nationwide cohort study, a total of 63 532 patients with RA, with 26 050 biological treatment episodes (TNFi, rituximab, abatacept or tocilizumab) and 76 304 general population controls, were followed between 2009 and 2017 until the first outcome event. The main outcome was hospitalisation or death due to lower GI perforations, identified according to a prespecified list of ICD-10 (International Classification of Diseases, 10th revision) codes. Inverse probability of treatment weighting was used for adjustment. RESULTS: The sex-standardised and age-standardised incidence rates of lower GI perforations were 1.1 (95% CI 1.0 to 1.3) events per 1000 person-years among general population controls, 1.6 (1.5-1.7) among bionaïve patients and ranged from 1.8 (1.4-3.6) (TNFi) to 4.5 (2.7-10.4) (tocilizumab) among biologics-treated patients. After adjustment for glucocorticoid use, the risk in bionaïve, TNFi-treated, abatacept-treated or rituximab-treated patients with RA was no longer different from the general population, while for tocilizumab it remained significantly higher. Comparing tocilizumab to TNFi, the adjusted HR for lower GI perforations was 2.2 (1.3-3.8), corresponding to one additional GI perforation per 451 patient-years treated with tocilizumab instead of TNFi. CONCLUSION: Tocilizumab was associated with a higher risk of lower GI perforations compared with alternative biologics. In absolute numbers, the risk remained low on all biologics commonly used to treat RA, but the accumulated evidence across settings and outcome definitions supports that this risk should be considered in treatment guidelines for RA.
引用
- Barbulescu A, Delcoigne B, Askling J, et al. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study. RMD Open. 2020. PMID: 32669452. doi:10.1136/rmdopen-2020-001201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。